Overview of the Liver Step 1 Practice Exam

Correct: Zone 3 (centrilobular)
Acetaminophen toxicity causes Zone 3 (centrilobular) necrosis because CYP2E1-catalyzed metabolism is highest in hepatocytes surrounding the central vein, producing the reactive NAPQI intermediate. Zone 3 is the hypoxic zone with lower antioxidant capacity, making it vulnerable.

A— Zone 1 (periportal) is affected by prehepatic injury (viral hepatitis inflammation starts here).
C— Zone 2 is rarely selective in toxin-mediated injury.
D, E— Acetaminophen causes zonal (not pan-acinar) necrosis.

Correct: Zone 1 (periportal)
Acute viral hepatitis triggers Zone 1 (periportal) inflammation with lymphocytic infiltration around the portal tracts. The immune response is activated by antigen-presenting cells and infiltrating T cells in the portal tract, leading to hepatocyte damage in the periportal zone.

B— Zone 3 is affected by toxins and hypoxia, not viral inflammation.
C— Zone 2 is rarely the primary site.
D, E— Not the predominant pattern in acute viral hepatitis.

Correct: B — Ascites requires portal hypertension; edema can occur from hypoalbuminemia without portal HTN
Ascites pathophysiology in cirrhosis involves three mechanisms: (1) portal hypertension, (2) hypoalbuminemia (↓oncotic pressure), and (3) renal sodium retention (activation of RAAS/SNS). Portal hypertension is the KEY distinguishing driver—it increases splanchnic capillary pressure despite reduced plasma oncotic pressure. Peripheral edema from hypoalbuminemia alone (e.g., nephrotic syndrome) does NOT produce ascites unless portal HTN coexists.

A— Incorrect; ascites requires portal HTN, edema alone does not.
C, D, E— Oversimplifications or inaccurate pathophysiology.

Correct: B — Impaired ammonia detoxification (urea cycle dysfunction)
Hepatic encephalopathy results from impaired ammonia detoxification. The liver normally converts ammonia (from amino acid catabolism) to urea via the urea cycle. In cirrhosis with hepatic synthetic failure, this capacity is lost—ammonia accumulates, crosses the blood-brain barrier (fat-soluble), and causes cerebral edema and neuronal dysfunction (asterixis, confusion, coma).

A— Jaundice is from bilirubin; not the primary cause of encephalopathy.
C— Unconjugated hyperbilirubinemia causes kernicterus in neonates, not hepatic encephalopathy in adults.
D— Copper accumulation is Wilson disease (not typical cirrhosis).
E— Thrombocytopenia increases bleeding risk, not encephalopathy directly.

Correct: B — Albumin is synthesized exclusively by hepatocytes; long half-life (~20 days) reflects chronic protein synthetic capacity
Albumin is the most abundant plasma protein, synthesized exclusively by hepatocytes. With a half-life of approximately 20 days, it reflects cumulative hepatic synthetic function over weeks. In cirrhosis, impaired hepatocyte function and loss of hepatic mass reduce albumin synthesis, resulting in hypoalbuminemia and decreased plasma oncotic pressure—contributing to ascites and edema.

A— Albumin is not filtered by kidneys (too large).
C— Albumin is depleted in ascites, but that's a consequence, not the mechanism.
D— Kupffer cells do not degrade albumin.
E— Albumin correction requires restored hepatic synthesis, not transfusion.

Correct: B — Decreased hepatic synthesis of clotting factors (II, V, VII, IX, X; NOT VIII)
Hepatic synthetic dysfunction impairs production of most clotting factors (II, V, VII, IX, X), which are synthesized by hepatocytes and require vitamin K as a cofactor. In acute hepatic failure, these factors drop rapidly, causing prolonged PT/INR. Factor VIII is synthesized by endothelial cells, NOT hepatocytes, so it remains relatively preserved—a key distinction that helps differentiate hepatic coagulopathy from DIC.

A— Platelets affect bleeding time, not PT/INR.
C— Vitamin K deficiency is a separate cause; if due to biliary obstruction, vitamin K can correct PT, but in fulminant failure it doesn't.
D— DIC causes low platelets and elevated D-dimer; in liver failure, PT is disproportionately prolonged.
E— No evidence of autoimmune coagulopathy here.

Correct: B — Depletion of CoQ10 and intermediates in the mevalonate pathway
Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. This blocks the entire mevalonate pathway, depleting not only cholesterol but also downstream isoprenoid intermediates (farnesyl pyrophosphate, geranylgeranyl pyrophosphate) and CoQ10 (ubiquinone)—essential for ATP production in mitochondria. Muscle cells have high energy demands and are vulnerable to CoQ10 depletion, resulting in myopathy.

A— Statins are not directly toxic; the mechanism is metabolic.
C— Low LDL is the therapeutic goal; cell starvation doesn't cause myopathy.
D— Autoimmune myositis is rare and not the typical mechanism.
E— Statins do not block mtDNA replication.

Correct: B — Complete absence of UGT1A1 enzyme
Crigler-Najjar Type I is caused by complete absence of the UGT1A1 glucuronidase enzyme, resulting in severe unconjugated hyperbilirubinemia (>20 mg/dL in the first week of life). Without the ability to conjugate bilirubin, severe jaundice develops rapidly. Unconjugated bilirubin crosses the blood-brain barrier, causing kernicterus (bilirubin encephalopathy) with permanent neurological damage unless treated aggressively with phototherapy and/or exchange transfusion. Most patients require liver transplantation in infancy.

A— Reduced activity (30–50%) is Gilbert syndrome, which is benign.
C, D— These cause conjugated hyperbilirubinemia (Dubin-Johnson, Rotor), not unconjugated.
E— Not the genetic defect in Crigler-Najjar.

Correct: B — Gilbert syndrome
Gilbert syndrome is the most common cause of benign unconjugated hyperbilirubinemia, affecting 5–10% of the population. It results from a promoter polymorphism in the UGT1A1 gene causing 30–50% reduction in enzyme activity. Jaundice is typically mild (1–3 mg/dL) and often triggered by fasting, illness, exercise, or stress (as in this case). Liver enzymes are normal, and the condition is entirely benign with no long-term complications.

A— Crigler-Najjar Type II presents with higher bilirubin levels in infancy and responds to phenobarbital.
C— No hemolysis (normal reticulocyte count implied).
D, E— Would show elevated conjugated bilirubin or liver enzyme elevation.

Correct: B — Defective MRP2 transporter
Dubin-Johnson syndrome results from mutations in the MRP2 (multidrug resistance-associated protein 2) gene, which encodes a transporter responsible for secreting conjugated bilirubin and other organic anions into bile. Without functional MRP2, conjugated bilirubin accumulates within hepatocytes and is reabsorbed into blood (conjugated hyperbilirubinemia). The characteristic black or dark brown liver is caused by accumulation of a melanin-like pigment (possibly lipofuscin or altered bilirubin metabolites). The condition is benign with an excellent prognosis.

A— Crigler-Najjar causes unconjugated, not conjugated, hyperbilirubinemia.
C, D— These cause cirrhosis and systemic toxicity, not isolated hyperbilirubinemia.
E— Rotor syndrome is similar (conjugated hyperbilirubinemia) but liver color is normal (defect in OATP uptake, not secretion).

Correct: B — Pale or clay-colored (acholic) stools
Obstructive jaundice presents with the classic triad: (1) jaundice, (2) dark urine (bilirubinuria from conjugated bilirubin filtered by kidneys), and (3) pale/clay-colored stools. In biliary obstruction, bilirubin cannot reach the gut, so gut bacteria cannot convert it to stercobilin (which gives stool its brown color). The result is acholic (pale) stools. The elevated conjugated bilirubin is water-soluble and filtered by kidneys, causing bilirubinuria (dark urine).

A— Melena is from upper GI bleeding, not obstructive jaundice.
C— Steatorrhea is from fat malabsorption (bile salt deficiency), a secondary consequence.
D, E— Inconsistent with obstruction.

Correct: B — Elevated urobilinogen in urine; no bilirubinuria; dark stools
Hemolytic jaundice produces unconjugated (indirect) hyperbilirubinemia because RBC destruction releases hemoglobin, which is converted to unconjugated bilirubin in the reticuloendothelial system. Unconjugated bilirubin cannot be filtered by kidneys (fat-soluble, albumin-bound), so there is NO bilirubinuria. However, excess bilirubin reaches the gut → deconjugated by bacteria → urobilinogen → reabsorbed and excreted in urine (elevated urobilinogen) → stercobilin in stool (dark/brown, not pale).

A— Unconjugated bilirubin is NOT filtered; no bilirubinuria in hemolysis.
C— Pale stools occur in obstructive jaundice, not hemolytic.
D, E— Liver enzymes are typically normal in pure hemolysis.

Correct: B — Supersaturation of cholesterol in bile
Cholesterol gallstones form when bile becomes supersaturated with cholesterol. Three factors contribute: (1) increased cholesterol secretion into bile (obesity, estrogen), (2) decreased bile acid pool (enterohepatic circulation dysfunction), and (3) decreased lecithin. The classic risk factors are the 4 F's: Female, Fat, Forty, Fertile (plus family history, fast weight loss, liver disease). In this patient: female, obese (fat), older, multiparity (fertile), and on HRT (estrogen increases cholesterol secretion).

A— Pigment stones form in hemolysis or infections; not here.
C— Infection is secondary to stones, not primary.
D, E— These cause stasis but not supersaturation of cholesterol.

Correct: B — Pigment (bilirubin) stones from chronic hemolysis
Pigment gallstones form in chronic hemolytic anemias (sickle cell, hereditary spherocytosis, G6PD deficiency) because continuous RBC destruction releases hemoglobin → unconjugated bilirubin production overwhelms hepatic conjugation capacity → conjugated (and unconjugated) bilirubin accumulates in bile → precipitation of bilirubin salts and calcium (black pigment stones). Unconjugated hyperbilirubinemia is the driver, distinct from the cholesterol supersaturation in typical (metabolic) gallstones.

A— Cholesterol stones are associated with obesity/estrogen, not hemolysis.
C, D— Mixed stones can occur but pigment is the predominant stone type.
E— Hemolytic disease is a well-established risk factor.

Correct: B — Cholecystokinin (CCK) from I cells and secretin from S cells
Cholecystokinin (CCK) is released by duodenal I cells in response to fats and amino acids. CCK causes gallbladder contraction, relaxation of the sphincter of Oddi, and hepatic bile production. Secretin is released by duodenal S cells in response to acid and partially digested proteins. Secretin stimulates cholangiocytes (bile duct epithelium) to increase bicarbonate-rich bile secretion (alkalinization to neutralize stomach acid). Together, these hormones coordinate the postprandial release of nutrient-rich bile.

A— Gastrin and motilin are for gastric motility and acid secretion.
C— Somatostatin is inhibitory, not stimulatory.
D, E— Not the hormonal regulators of bile secretion.

Correct: B — Loss of gallbladder storage; continuous bile → bile salts reach colon → stimulation of colonic secretion
Postcholecystectomy diarrhea occurs in ~10–15% of patients. Normally, the gallbladder stores and concentrates bile during fasting. After a meal, CCK triggers contraction, releasing a bolus of concentrated bile into the duodenum. The terminal ileum reabsorbs ~95% of bile acids via enterohepatic circulation. After cholecystectomy, there is no storage—bile drips continuously into the duodenum. In the colon, unabsorbed bile acids stimulate secretion (increased cAMP, chloride secretion) → osmotic diarrhea. Cholestyramine (a bile acid sequestrant) binds these excess bile acids in the ileum, reducing their colonic delivery.

A— Bile salt loss is not the mechanism; reabsorption is reduced.
C, D— No pancreatic or surgical intestinal injury.
E— Not inflammation; normal healing occurs.

Correct: B — Fat malabsorption, vitamin A/D/E/K/B12 deficiency, increased oxalate kidney stones
The terminal ileum is the site of enterohepatic circulation of bile acids (~95% reabsorption) and vitamin B12 absorption (via intrinsic factor binding). Resection of the terminal ileum leads to: (1) reduced bile acid reabsorption → increased hepatic bile acid synthesis but insufficient pool → impaired fat emulsification → steatorrhea and fat-soluble vitamin (A, D, E, K) malabsorption; (2) B12 deficiency (pernicious anemia develops over 2–5 years); (3) increased colonic oxalate absorption → hyperoxaluria → kidney stones (calcium oxalate).

A— Hypercalcemia does not occur; rather, vitamin D deficiency and hypocalcemia result.
C— Fat malabsorption is a major consequence.
D— Opposite; reduced bile acid pool → reduced stone risk.
E— Hyperoxaluria is a consequence (not primary), but it increases stone risk.

Correct: B — Pancreatic head malignancy until proven otherwise
Courvoisier sign is the combination of painless jaundice + palpable, non-tender gallbladder enlargement. It is a classic teaching point for pancreatic head carcinoma. The tumor obstructs the common bile duct, causing jaundice and upstream bile backing up into the gallbladder (distention). In gallstone disease, the gallbladder wall becomes chronically inflamed and fibrosed, preventing distention (Courvoisier law). Thus, a distended gallbladder + painless jaundice = pancreatic malignancy until proven otherwise. This patient's demographics (age, smoking) and presentation (painless, weight loss) strongly support pancreatic cancer.

A— Acute cholecystitis would be painful (tender).
C, D, E— Do not typically present with a palpable gallbladder.

Correct: B — Unconjugated bilirubin crosses BBB; deposits in basal ganglia and brainstem
Kernicterus (bilirubin encephalopathy) occurs when unconjugated (indirect) hyperbilirubinemia is severe and prolonged. Unconjugated bilirubin is fat-soluble and can cross the immature blood-brain barrier in neonates (especially if premature or with hemolysis). Bilirubin deposits in lipid-rich structures—basal ganglia, brainstem nuclei, cerebellum—causing acute toxicity (lethargy, seizures, hypotonia) and chronic sequelae (choreoathetoid cerebral palsy, sensorineural hearing loss, ABR abnormalities). Phototherapy converts unconjugated bilirubin to lumirubin (water-soluble) for excretion without hepatic conjugation.

A— Conjugated bilirubin is water-soluble; cannot cross BBB.
C, D, E— Not the mechanism of kernicterus.

Correct: B — Induction of hepatic CYP and UGT enzyme expression
Crigler-Najjar Type II has reduced (not absent) UGT1A1 activity (~10% of normal). Phenobarbital is a potent CYP450 and glucuronidase inducer. By upregulating CYP and UGT enzyme expression in hepatocytes, phenobarbital increases the already-reduced UGT1A1 activity above the threshold needed for adequate bilirubin conjugation. This reduces unconjugated bilirubin levels and prevents kernicterus. Phenobarbital is ineffective in Crigler-Najjar Type I (complete absence of UGT1A1; no enzyme to induce).

A— Bilirubin production is normal; not the target.
C, D, E— Not mechanisms of phenobarbital action.